Cost-Effectiveness of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma in Taiwan

Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.08.705
https://www.valueinhealthjournal.com/article/S1098-3015(16)31285-2/fulltext
Section Title : Cost-Effectiveness Studies
Section Order : 2298
First Page : A811
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)31285-2&doi=10.1016/j.jval.2016.08.705
HEOR Topics :
Tags :
Regions :